Dintsios CM - Search Results

1

Questioning Conclusions and Statements on the German HTA System: A Critical Perspective.

Tomeczkowski J, Heidbrede T, Leverkus F, Schmitter S, Dintsios CM, Osowski U, Herrmann KH, Bluhmki T, Marx A, Eichinger B, Basic E, Bussilliat P, Dietrich ES. Tomeczkowski J, et al. Among authors: dintsios cm. Clin Pharmacol Ther. 2024 May 9. doi: 10.1002/cpt.3296. Online ahead of print. Clin Pharmacol Ther. 2024. PMID: 38721790 No abstract available.

2

Treatment response in hemato-oncology in the context of the German early benefit assessment of drugs compared to clinical practice.

Baltes N, Icks A, Dintsios CM. Baltes N, et al. Among authors: dintsios cm. J Evid Based Med. 2023 Dec;16(4):451-454. doi: 10.1111/jebm.12575. Epub 2023 Dec 21. J Evid Based Med. 2023. PMID: 38130148 No abstract available.

3

How Far is Germany From Value-Based Pricing 10 Years After the Introduction of AMNOG?

Dintsios CM, Chernyak N. Dintsios CM, et al. Appl Health Econ Health Policy. 2022 May;20(3):287-290. doi: 10.1007/s40258-021-00712-x. Epub 2021 Dec 29. Appl Health Econ Health Policy. 2022. PMID: 34964091 Free PMC article. No abstract available.

4

A decade of early benefit assessment of ophthalmic drugs in Germany: success story or not?

Dintsios CM. Dintsios CM. Expert Rev Pharmacoecon Outcomes Res. 2022 Mar;22(2):283-297. doi: 10.1080/14737167.2021.1930532. Epub 2021 Jul 12. Expert Rev Pharmacoecon Outcomes Res. 2022. PMID: 33999735

5

Health care utilization and excess costs after pelvic fractures among older people in Germany.

Andrich S, Haastert B, Neuhaus E, Frommholz K, Arend W, Ohmann C, Grebe J, Vogt A, Brunoni C, Jungbluth P, Thelen S, Dintsios CM, Windolf J, Icks A. Andrich S, et al. Among authors: dintsios cm. Osteoporos Int. 2021 Oct;32(10):2061-2072. doi: 10.1007/s00198-021-05935-1. Epub 2021 Apr 10. Osteoporos Int. 2021. PMID: 33839895 Free PMC article.

6

Health Care Use and Costs in Individuals With Diabetes With and Without Comorbid Depression in Germany: Results of the Cross-sectional DiaDec Study.

Brüne M, Linnenkamp U, Andrich S, Jaffan-Kolb L, Claessen H, Dintsios CM, Schmitz-Losem I, Kruse J, Chernyak N, Hiligsmann M, Hermanns N, Icks A. Brüne M, et al. Among authors: dintsios cm. Diabetes Care. 2021 Feb;44(2):407-415. doi: 10.2337/dc19-2487. Epub 2020 Dec 14. Diabetes Care. 2021. PMID: 33318124

7

Predictors of negotiated prices for new drugs in Germany.

Gandjour A, Schüßler S, Hammerschmidt T, Dintsios CM. Gandjour A, et al. Among authors: dintsios cm. Eur J Health Econ. 2020 Sep;21(7):1049-1057. doi: 10.1007/s10198-020-01201-z. Epub 2020 May 25. Eur J Health Econ. 2020. PMID: 32451745 Free PMC article.

8

The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany.

Dintsios CM, Beinhauer I. Dintsios CM, et al. Health Econ Rev. 2020 Mar 14;10(1):7. doi: 10.1186/s13561-020-00263-2. Health Econ Rev. 2020. PMID: 32172494 Free PMC article.

9

Failure due to formal reasons within German benefit assessment of medicinal products: the dilemma between marketing authorization and HTA.

Molitor M, Dintsios CM. Molitor M, et al. Among authors: dintsios cm. Expert Rev Pharmacoecon Outcomes Res. 2021 Feb;21(1):145-157. doi: 10.1080/14737167.2020.1729131. Epub 2020 Feb 20. Expert Rev Pharmacoecon Outcomes Res. 2021. PMID: 32043904

10

Determinants of Orphan Drug Prices in Germany.

Worm F, Dintsios CM. Worm F, et al. Among authors: dintsios cm. Pharmacoeconomics. 2020 Apr;38(4):397-411. doi: 10.1007/s40273-019-00872-8. Pharmacoeconomics. 2020. PMID: 31903523

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

58 results

Search Page